Angelique Silva-Da

Avenue De La Côte De Nacre
Caen, 14000, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 8 publications

Bruton's tyrosine kinase inhibitors and cardiovascular risk: a meta-analysis.

Bruton's tyrosine kinase inhibitors and cardiovascular risk: a meta-analysis.

Journal: European heart journal

Published: December 18, 2025

Association Between the Renin-Angiotensin System and Ibrutinib-Related Cardiovascular Adverse Events: A Translational Cohort Study.

Association Between the Renin-Angiotensin System and Ibrutinib-Related Cardiovascular Adverse Events: A Translational Cohort Study.

Journal: Biomedicines

Published: June 04, 2025

Ibrutinib and acalabrutinib use and risk of incident atrial fibrillation: a propensity-matched analysis.

Ibrutinib and acalabrutinib use and risk of incident atrial fibrillation: a propensity-matched analysis.

Journal: Experimental hematology & oncology

Published: December 10, 2024

Neurocognitive impairment in females with breast cancer treated with endocrine therapy and CDK4/6 inhibitors: a pharmacovigilance study using the World Health Organization's database.

Neurocognitive impairment in females with breast cancer treated with endocrine therapy and CDK4/6 inhibitors: a pharmacovigilance study using the World Health Organization's database.

Journal: Frontiers in pharmacology

Published: August 16, 2023

Atrial Fibrillation Incidence Associated With Exposure to Anticancer Drugs Used as Monotherapy in Clinical Trials.

Atrial Fibrillation Incidence Associated With Exposure to Anticancer Drugs Used as Monotherapy in Clinical Trials.

Journal: JACC. CardioOncology

Published: October 06, 2022

Cardiovascular immunotoxicities associated with immune checkpoint inhibitors: a safety meta-analysis.

Cardiovascular immunotoxicities associated with immune checkpoint inhibitors: a safety meta-analysis.

Journal: European heart journal

Published: March 19, 2021

Recurrence of Immune-Related Adverse Events After Immune Checkpoint Inhibitor Rechallenge-Reply.

Recurrence of Immune-Related Adverse Events After Immune Checkpoint Inhibitor Rechallenge-Reply.

Journal: JAMA oncology

Published: September 24, 2020

Immune Checkpoint Inhibitor Rechallenge After Immune-Related Adverse Events in Patients With Cancer.

Immune Checkpoint Inhibitor Rechallenge After Immune-Related Adverse Events in Patients With Cancer.

Journal: JAMA oncology

Published: April 17, 2020

Showing 1-8 of 8

Last Updated: 09/26/2026